The aim of the study is to explore the function of human anti-immunogloblin autoantibody responses and why they are present in humans. Furthermore; through the study team aims to identify subjects with anti-Vh autoantibody responses that also bind to GSK2862277 with the possibility of confirming the relationship of pre-existing anti-drug antibodies (ADAs) and propensity for adverse events in humans dosed with GSK2862277.
Participation: 4000 serum samples from the Cambridge BioResource volunteers were provided for this study.
Organisation: This study is organised by Dr Andrew Bayliffe from GlaxoSmithKline.
